Last reviewed · How we verify
Ceftazidime-avibactam
Ceftazidime-avibactam is a Beta-lactam/beta-lactamase inhibitor combination Small molecule drug developed by Qilu Pharmaceutical Co., Ltd.. It is currently FDA-approved for Complicated urinary tract infections (cUTI) caused by susceptible gram-negative bacteria, Complicated intra-abdominal infections (cIAI) caused by susceptible gram-negative bacteria, Hospital-acquired bacterial pneumonia (HABP) and ventilator-associated bacterial pneumonia (VABP). Also known as: Avycaz.
Ceftazidime-avibactam is a combination of a third-generation cephalosporin antibiotic and a beta-lactamase inhibitor that kills bacteria by inhibiting cell wall synthesis while protecting the antibiotic from enzymatic degradation.
Ceftazidime-avibactam is a combination antibiotic used to treat severe Gram-negative bacterial infections. It works by inhibiting bacterial penicillin-binding proteins, a mechanism that is targeted by the small molecule ceftazidime, which is combined with avibactam to enhance its effectiveness.
At a glance
| Generic name | Ceftazidime-avibactam |
|---|---|
| Also known as | Avycaz |
| Sponsor | Qilu Pharmaceutical Co., Ltd. |
| Drug class | Beta-lactam/beta-lactamase inhibitor combination |
| Target | Penicillin-binding proteins (PBPs); serine beta-lactamases |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | FDA-approved |
Mechanism of action
Ceftazidime is a broad-spectrum cephalosporin that binds to penicillin-binding proteins and disrupts bacterial cell wall synthesis. Avibactam is a non-beta-lactam beta-lactamase inhibitor that protects ceftazidime from degradation by serine beta-lactamases, including extended-spectrum beta-lactamases (ESBLs), AmpC beta-lactamases, and some carbapenemases, thereby restoring ceftazidime's activity against resistant gram-negative and gram-positive bacteria.
Approved indications
- Complicated urinary tract infections (cUTI) caused by susceptible gram-negative bacteria
- Complicated intra-abdominal infections (cIAI) caused by susceptible gram-negative bacteria
- Hospital-acquired bacterial pneumonia (HABP) and ventilator-associated bacterial pneumonia (VABP)
- Aerobic gram-negative bacterial infections in patients with limited treatment options
Common side effects
- Diarrhea
- Nausea
- Vomiting
- Headache
- Phlebitis at infusion site
- Elevated liver enzymes
Key clinical trials
- Individualized Precision Therapy With Ceftazidime and Avibactam Guided by PK/PD in Geriatric Populations
- Different Administration Regimens of CAZ-AVI in Combination With ATM for the Treatment of CR-GNB (PHASE4)
- Safety, Pharmacokinetics and Efficacy of BV100 Plus Low Dose Polymyxin B Plus Ceftazidime/Avibactam, or Plus Cefiderocol in Patients With Pulmonary and Extrapulmonary Infections Due to Carbapenem-resistant Acinetobacter Baumannii-calcoaceticus Complex (PHASE2)
- A Study to Evaluate the Efficacy and Safety of Meropenem and Pralurbactam in HABP/VABP (PHASE3)
- Effect of Ceftazidime-Avibactam on Carbapenemase-Producing Klebsiella Pneumoniae
- PK/PD Relationship of CAZ/AVI and FOS in the Treatment of Patients With Infections Due to CRE
- A Study to Learn About the Study Medicine - Zavicefta in Patients With Sepsis or Loss of Kidney Function in Japan
- Efficacy of Empirical Anti-Infective Therapy in Neutropenic Febrile Patients.
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Ceftazidime-avibactam CI brief — competitive landscape report
- Ceftazidime-avibactam updates RSS · CI watch RSS
- Qilu Pharmaceutical Co., Ltd. portfolio CI
Frequently asked questions about Ceftazidime-avibactam
What is Ceftazidime-avibactam?
How does Ceftazidime-avibactam work?
What is Ceftazidime-avibactam used for?
Who makes Ceftazidime-avibactam?
Is Ceftazidime-avibactam also known as anything else?
What drug class is Ceftazidime-avibactam in?
What development phase is Ceftazidime-avibactam in?
What are the side effects of Ceftazidime-avibactam?
What does Ceftazidime-avibactam target?
Related
- Drug class: All Beta-lactam/beta-lactamase inhibitor combination drugs
- Target: All drugs targeting Penicillin-binding proteins (PBPs); serine beta-lactamases
- Manufacturer: Qilu Pharmaceutical Co., Ltd. — full pipeline
- Therapeutic area: All drugs in Infectious Disease
- Indication: Drugs for Complicated urinary tract infections (cUTI) caused by susceptible gram-negative bacteria
- Indication: Drugs for Complicated intra-abdominal infections (cIAI) caused by susceptible gram-negative bacteria
- Indication: Drugs for Hospital-acquired bacterial pneumonia (HABP) and ventilator-associated bacterial pneumonia (VABP)
- Also known as: Avycaz
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing